ZFZachary Finley

Zachary Finley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zachary Finley has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety of Anteromedial Portals in Elbow Arthroscopy: A Systematic Review of Cadaveric Studies

    by Tucker Cushing, Zachary Finley, Michael J. O'BRien, Felix H. Savoie, Leann Myers, Gleb Medvedev

    Purpose: To systematically review available literature comparing location and safety of 2 common anteromedial portals with nearby neurovascular structures in cadaveric models and to determine the correct positioning and preparation of the joint before elbow arthroscopy. Methods: The review was devised in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐analyses guidelines. Inclusion criteria consisted of original, cadaveric studies performed by experienced surgeons on male or female elbows evaluating anteromedial portal placement with regard to proximity of the arthroscope to neurovascular structures. Exclusion criteria consisted of case reports, clinical series, non–English language studies, and noncadaveric studies. Statistical analysis was done to measure reviewer reliability after scoring of each study. Results: During screening, 2,596 studies were identified, and 10 studies met final inclusion as original, cadaveric investigations of anteromedial portal proximity to neurovascular structures. The difference in distance between proximal and distal portals was <1 mm for the brachial artery and <1.5 mm for the medial antebrachial cutaneous nerve, whereas the ulnar nerve was 4.17 mm further from the distal portal and the median nerve was 5.07 mm further from the proximal portal. Joint distension increased the distances of neurovascular structures to portal sites, with the exception of the ulnar nerve in distal portals. Elbow flexion to 90° increased distances of all neurovascular structures to portal sites. Conclusion: The results show that the proximal anteromedial portal puts fewer structures at risk compared with the distal portal. Elbows in 90° flexion with joint distension carry a lower risk for neurovascular injury during portal placement. These findings suggest the proximal anteromedial portal to be the safer technique in anteromedial arthroscopy of the elbow. Clinical Relevance: Discrepancies in placement of portals have existed in the literature, indicating differing safety margins regarding surrounding neurovascular anatomy. The present study aims to link together the literature‐based evidence to describe the safest anteromedial portal variation.


  • Outcomes of Hip Arthroscopy in Patients Aged 50 Years or Older Compared With a Matched‐Pair Control of Patients Aged 30 Years or Younger

    by Benjamin G. Domb, Dror Linder, Zachary Finley, Itamar B. Botser, Austin Chen, Joseph Williamson, Asheesh Gupta

    Purpose: Age has been suggested as a negative prognostic factor for hip arthroscopy. The purpose of this study was to compare patient characteristics and outcomes after hip arthroscopy in patients aged 50 years or older with a matched control group of patients aged 30 years or younger at a minimum postoperative follow‐up of 2 years. Methods: Between September 2008 and March 2010, data were prospectively collected on all patients aged 50 years or older undergoing primary hip arthroscopy. Fifty‐two patients met our inclusion and matching criteria, of whom all 52 (100%) were available for follow‐up at a minimum of 2 years. This cohort was compared with a matched‐pair control group of patients aged 30 years or younger who underwent similar procedures. Results: The mean age of the study group was 54.8 years (range, 50 to 69 years), and that of the control group was 20.3 years (range, 13 to 30 years). The groups were matched at a 1:1 ratio, including 18 male patients (34.6%) and 34 female patients (65.4%) in each group, with a mean follow‐up period of 32 months (range, 24 to 54 months). In the younger control group, the score improvement from preoperatively to 2 years' follow‐up was 62.9 to 84.2 for the modified Harris Hip Score, 60.5 to 84.2 for the Non‐Arthritic Hip Score, 63.1 to 86.5 for the Hip Outcome Score–Activities of Daily Living, and 42.2 to 72.7 for the Hip Outcome Score–Sport‐Specific Subscale. In the older study group, the score improvement from preoperatively to 2 years' follow‐up was 61.2 to 82.2 for the modified Harris Hip Score, 59.9 to 80.4 for the Non‐Arthritic Hip Score, 63.9 to 83 for the Hip Outcome Score–Activities of Daily Living, and 41.2 to 64.6 for the Hip Outcome Score–Sport‐Specific Subscale. All improvements in both groups were statistically significant at the 2‐year postoperative follow‐up ( P < .001). There was no significant difference for all patient‐reported outcome (PRO) scores at final follow‐up between both groups. When we compared the change in PRO scores (Δ) from preoperatively to 2 years postoperatively, there was no significant difference between both groups. The overall survivorship rate was 98.1% for the younger control group and 82.7% for the older study group. Conclusions: Survivors aged 50 years or older show similar improvement to patients aged 30 years or younger in PRO and patient satisfaction scores. The 2‐year survivorship rate was 98.1% for the younger control group and 82.7% for the older study group. Therefore we believe that hip arthroscopy should be considered a valid treatment option when treating hip pain in patients aged 50 years or older with a Tönnis arthritic grade of 0 or 1. Older patients should be counseled on the possibility of later conversion to total hip arthroplasty. Future work may include development of a decision‐making tool to assess for prognosis to better delineate the indications for hip arthroscopy in the older population. Level of Evidence: Level III, therapeutic case‐control study.